Predict your next investment

Corporate Venture
boehringer-ingelheim-venture.com

See what CB Insights has to offer

Investments

76

Portfolio Exits

8

Funds

1

About Boehringer Ingelheim Venture Fund

The Boehringer Ingelheim Venture Fund will be seeking to provide initial investments in seed or series A funding. Opening investments of up to €2 million per venture will be made at the early stage with subsequent staged investments made to align with each venture's progress, up to a total of €10-15 million per venture over its life.

Boehringer Ingelheim Venture Fund Headquarter Location

Binger Strasse 173

Ingelheim am Rhein, D-55216,

Germany

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Boehringer Ingelheim Venture Fund News

Digital health news, funding roundup in the prior week; June 20, 2022

Jun 20, 2022

Headspace launches leadership program; COVID vaccines for babies okayed; BoA funds community health Top Health News Hong Kong Science and Technology Parks Corporation partnered with global research-driven biopharmaceutical company Boehringer Ingelheim Venture Fund Limited in a strategic co-incubation collaboration to promote and nurture startups on research and development for infectious diseases and immunology. Programme incubatees will also benefit from HKSTP’s rapidly-growing biotech R&D capabilities including the HKSTP Institute for Translational Research (ITR), enabling biomedical startups to turn their innovative biomedical technologies to life-changing impact for patients and society. Also available to startups is HKSTP’s Incu-Bio program providing dedicated biotech mentorship, business matching, entrepreneur-in-residence, and access to R&D facilities and the Science Parks’ diverse talent pool. Bank of America committed $40 million in low-cost, long-term capital to finance the development and expansion of community health care centers and other primary care facilities across the United States. Bank of America will partner with non-profit community development financial institutions to distribute the funding. In addition, Bank of America will provide $100,000 in philanthropic grants to help with CDFI operational costs and help spark the creation of new health centers. mphrX, developer of Minerva, a Healthcare Data Platform as a Service,  announced its partnership with Mount Sinai Health System to deploy the Minerva platform to enable real-time clinical data sharing designed to meet the 21st Century Cures Act requirements. Minerva will integrate with the clinical source systems at Mount Sinai to create a real-time longitudinal health record. Aural Analytics, a clinical-grade speech analytics company, announced a partnership with Koneksa, a digital biomarker development company, to further strengthen its platform and research capabilities using Aural Analytics’ technology, Speech Vitals. Aural Analytics’ Speech Vitals will provide additional value on top of what those existing tools provide so that clinicians can make better decisions. Headspace Health, a provider of a digital mental health platform, announced the launch of a leadership education program to equip managers with science-backed practices to drive cultural change in organizations, support mental health and well-being in the workplace, and improve employee engagement, productivity, and retention. The Leadership Workshop Series will be the first of many offerings in a growing culture services program from Headspace Health that aims to bolster self-compassion among leaders and prepare them to engage in meaningful conversations with their teams about mental health, burnout and stress in a manner that fosters psychological safety and compassion. CDC Director Rochelle Walensky  endorsed the Advisory Committee on Immunization Practices’ recommendation that all children 6 months through 5 years of age should receive a COVID-19 vaccine. This expands eligibility for vaccination to nearly 20 million additional children and means that all Americans ages 6 months and older are now eligible for vaccination. Parents and caregivers can now get their children 6 months through 5 years of age vaccinated with the Pfizer-BioNTech or Moderna vaccines to better protect them from COVID-19. M&A CONMED Corporation, a medical technology company that provides surgical devices and equipment for minimally invasive procedures., completed its  acquisition of In2Bones, a developer, manufacturer, and distributor of medical devices for the treatment of disorders and injuries of the upper and lower extremities Bardavon Health Innovation, a provider of musculoskeletal health solutions in the physical therapy space,  acquired PeerWell, a consumer-focused musculoskeletal health application to create a truly hybrid treatment solution Enko, a crop health company, acquired proprietary DNA-encoded libraries and technology enablement from drug discovery service company X-Chem Lumanity, a healthcare data company,  acquired Endpoint Outcomes, a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life Donaldson Company, a provider of innovative filtration products and solutions, acquired Purilogics, an early-stage biotechnology company that leverages a novel technology platform for the development of best-in-class membrane chromatography products The U.S. Supreme Court unanimously  ruled  that the Department of Health and Human Services acted unlawfully by reducing drug reimbursement rates for certain hospital groups without conducting a survey. The case revolves around the 340B drug pricing program Onkos Surgical, a developer of solutions for musculoskeletal oncology and complex orthopaedic conditions, entered into a definitive agreement with Stryker to acquire its Juvenile Tumour System, which enables limb stabilization and growth in pediatric patients affected by bone cancers, severe arthropathy, severe trauma, revisions, oncology and malignant diseases Medical device company ResMed entered into a definitive agreement to acquire MEDIFOX DAN, a German out-of-hospital software solutions for providers in major settings OrthoPediatrics, a company focused on advancing the field of pediatric orthopedics, entered an agreement to acquire Pega Medical, a bioengineering services company Digital Health Acquisition Corporation, a a special purpose acquisition company, signed a definitive agreement to acquire VSee Lab, a telehealth software company, and iDoc Telehealth Solutions, a neurocritical care and intensive care telehealth provider GBS, a life sciences company developing non-invasive, real-time diagnostic testing for patients and their primary health practitioners at point of care, entered into an exclusivity agreement for the acquisition of Intelligent Fingerprinting Limited, developer of a portable Drug Screening System Constellation4 Health, a healthcare technology innovator, acquired Vulcan Health, a digital referral management platform Medical technology company Boston Scientific Corporation entered into a definitive agreement with Synergy Innovation to acquire its majority stake of M.I.Tech, a traded Korean manufacturer and distributor of medical devices for endoscopic and urologic procedures Health services firm Optum UK acquired  healthcare technology company EMIS Group TELUS, a communications technology company, entered into a definitive agreement to acquire LifeWorks, a provider of digital and in-person solutions that support the total wellbeing of individuals Funding Roundup

Boehringer Ingelheim Venture Fund Investments

76 Investments

Boehringer Ingelheim Venture Fund has made 76 investments. Their latest investment was in ImCheck Therapeutics as part of their Series C on June 6, 2022.

CBI Logo

Boehringer Ingelheim Venture Fund Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

6/13/2022

Series C

ImCheck Therapeutics

$103M

No

4

3/4/2022

Series A - III

TeleVet

Yes

2

3/3/2022

Seed VC

ArrePath

$20M

Yes

12

2/16/2022

Series A

Subscribe to see more

$99M

Subscribe to see more

10

2/7/2022

Seed VC - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/13/2022

3/4/2022

3/3/2022

2/16/2022

2/7/2022

Round

Series C

Series A - III

Seed VC

Series A

Seed VC - III

Company

ImCheck Therapeutics

TeleVet

ArrePath

Subscribe to see more

Subscribe to see more

Amount

$103M

$20M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

4

2

12

10

10

Boehringer Ingelheim Venture Fund Portfolio Exits

8 Portfolio Exits

Boehringer Ingelheim Venture Fund has 8 portfolio exits. Their latest portfolio exit was NBE Therapeutics on December 10, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/10/2020

Acquired

$99M

4

7/15/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

6/10/2019

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

4/18/2019

IPO

Subscribe to see more

$99M

Subscribe to see more

10

9/13/2018

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/10/2020

7/15/2019

6/10/2019

4/18/2019

9/13/2018

Exit

Acquired

Acquired

Acquired

IPO

Acquired

Companies

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

Boehringer Ingelheim Venture Fund Fund History

1 Fund History

Boehringer Ingelheim Venture Fund has 1 fund, including Boehringer Ingelheim Venture Fund I.

Closing Date

Fund

Fund Type

Status

Amount

Sources

1/3/2018

Boehringer Ingelheim Venture Fund I

$300.64M

2

Closing Date

1/3/2018

Fund

Boehringer Ingelheim Venture Fund I

Fund Type

Status

Amount

$300.64M

Sources

2

Boehringer Ingelheim Venture Fund Team

2 Team Members

Boehringer Ingelheim Venture Fund has 2 team members, including current Senior Vice President, Detlev Mennerich.

Name

Work History

Title

Status

Detlev Mennerich

Senior Vice President

Current

James Kasuboski

BridgeBio Pharma, Apple Tree Partners, SV Health Investors, The Salk Institute for Biological Studies, and University of Notre Dame

Senior Director

Current

Name

Detlev Mennerich

James Kasuboski

Work History

BridgeBio Pharma, Apple Tree Partners, SV Health Investors, The Salk Institute for Biological Studies, and University of Notre Dame

Title

Senior Vice President

Senior Director

Status

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.